Skip to main content
Fig. 5 | Trials

Fig. 5

From: Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study

Fig. 5

Schedule of enrollment, interventions and assessments in the NORD-STAR study, treatment part 1. *This visit may be replaced by a telephone contact. **Measured if clinically indicated. ***Blinding of joint-assessor is not necessary since the patient has not been randomized to a treatment arm at screening. ****If tocilizumab is given intravenously, the weight is measured at all visits. Abbreviations: ET early termination, MTX methotrexate, SSZ sulphasalazine, HCQ hydroxychloroquine, i.a. intra-articular, CZP certolizumab-pegol, ABA abatacept, TCZ tocilizumab, RA rheumatoid arthritis, SJC swollen joint count, TJC tender joint count, RF rheumatoid factor, ACPA anti-citrullinated protein antibodies, ANA anti-nuclear antibody, PPD purified protein derivate, VAS Visual Analogue Scale, HAQ Health Assessment Questionnaire, WPAI, Work Productivity Activity Impairment, EQ5D EuroQol 5 dimensions, PASS, Patient Acceptable Symptom State, FACIT Functional Assessment of Chronic Illness Therapy, SF36 Short Form 36, CDAI Clinical Disease Activity Index, DAS Disease Activity Score

Back to article page

Trials

ISSN: 1745-6215